Celyad OncologyCLYYF 28 Current Ratio is 1.92 as of Dec. 2025, which is 37% below its 10-year median of 3.04. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Celyad Oncology ranks worse than 69.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Celyad Oncology's current ratio for the quarter that ended in Dec. 2025 was 1.92.
Celyad Oncology has a current ratio of 1.92. It generally indicates good short-term financial strength.
The historical rank and industry rank for Celyad Oncology's Current Ratio or its related term are showing as below:
CLYYF'
s Current Ratio Range Over the Past 10 Years
Min: 1.42 Med: 3.04 Max: 7.57
Current: 1.92
During the past 13 years, Celyad Oncology's highest Current Ratio was 7.57. The lowest was 1.42. And the median was 3.04.
CLYYF's Current Ratio is ranked worse than 69.92% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs CLYYF: 1.92
Celyad Oncology (OTCPK:CLYYF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Celyad Oncology Current Ratio Related Terms
Celyad Oncology Current Ratio Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Celyad Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Current Ratio of 1.92 as of Dec. 2025. This is 37% below median its historical median of 3.04. Over the past decade, Celyad Oncology's Current Ratio has ranged from 1.42 to 7.57. According to the industry distribution chart, Celyad Oncology ranks #990 out of 1416 companies in the Biotechnology industry, placing it in the top 69.9%.
Is Celyad Oncology's Current Ratio too high?
Celyad Oncology's current Current Ratio of 1.92 is 37% below median its 10-year median of 3.04. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 7.57. The Biotechnology industry median Current Ratio is 3.89. Celyad Oncology's value of 1.92 is 50.6% below this industry median. Based on the distribution chart, Celyad Oncology ranks #990 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #990 out of 1416 companies for Current Ratio. This places Celyad Oncology in the lower half of its industry. The industry median Current Ratio is 3.89. Celyad Oncology's value of 1.92 is 50.6% below this benchmark. Historically, Celyad Oncology's own Current Ratio has ranged from 1.42 to 7.57 over the past decade. While the company's 10-year median is 3.04 vs. the industry median of 3.89, Celyad Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current Current Ratio of 1.92 is 50.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Current Ratio is 1.92, which is 37% below median its own 10-year median of 3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current Current Ratio is 1.92, which is 37% below median its 10-year median of 3.04 and 50.6% below the Biotechnology industry median of 3.89. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Current Ratio is 1.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Current Ratio: 1.92 (37% below median its 10-year median of 3.04)
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
Industry Position: 50.6% below the Biotechnology median (#990 of 1416)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
